1. Scrip
  2. >>Therapy Areas
  3. >>Dermatological

Clinuvel Plots Competition To Incyte In Vitiligo Space

Trial Aimed At Expanding Label On Scenesse

 
• By Kevin Grogan

The Australian company is steadily growing its photoprotective drug in adults with erythropoietic protoporphyria but also sees a big opportunity in the pigment loss disorder.

Vitiligo
Winnie Harlow: Model and entrepreneur who has vitiligo • Source: Shutterstock

There were no approved drugs for vitiligo until Opzelura got the green light in the US this summer but Australia's CLINUVEL PHARMACEUTICALS LIMITED is hoping that Scenesse, already marketed for a rare light intolerance disorder, will join Incyte Corporation's topical therapy on the market for the pigment loss condition in the not-too-distant future.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Dermatological

More from Therapy Areas

Zai’s R&D Head Touts ‘Beauty’ Of Novel Internal Assets

 
• By Dexter Jie Yan

Two potentially first-in-class molecules signify Zai Lab’s renewed drive for the in-house discovery of drugs that it requires “to be innovative, differentiated and to have the potential to make a big difference for patients,” its global R&D head tells Scrip.

J&J’s Imaavy Approval Is The Starting Line For Pipeline-In-A-Product Strategy

 
• By Jessica Merrill

The company’s FcRn inhibitor nipocalimab was approved by the US FDA for generalized myasthenia gravis (gMG), where it will join a competitive market.

GSK Chief Optimistic About BD Despite Volatile Environment

 
• By Kevin Grogan

Emma Walmsley tells Scrip that the "biotech market is under a certain degree of pressure," so reasonably priced deals are available.